Safety data sheet database information............

16 millones+ hojas de datos de seguridad libremente buscables con descargas en PDF.

A database of ingredients in brand-name household products linked to health information from Material Safety Data Sheets (MSDS) provided by manufacturers. The database is designed to help answer the following typical questions: *What are the chemical ingredients and their percentage in specific brands? *Which products contain specific chemical ingredients? *Who manufactures a specific brand? How do I contact this manufacturer? *What are the acute and chronic effects of chemical ingredients in a specific brand? *What other information is available about chemicals in the toxicology-related databases of the National Library of Medicine? NLM and its Contractor (the Database Providers) do not test products nor investigate to determine if this information is complete or accurate.

16 millioner+ sikkerhetsdatablader (SDS) fritt søkbare med PDF-nedlastinger.

This database links over 4,000 consumer brands to health effects from Material Safety Data Sheets (MSDS) provided by the manufacturers and allows scientists and consumers to research products based on chemical ingredients.

The Household Products Database of the National Library of Medicine is based on the Consumer Product Information Database ©2001-2013 by DeLima Associates. All rights reserved.

The Chemical and Product Categories database (CPCat) catalogs the use of over 40,000 chemicals and their presence in different consumer products. The chemical use information is compiled from multiple sources while product information is gathered from publicly available Material Safety Data Sheets (MSDS). EPA researchers are evaluating the possibility of expanding the database with additional product and use information.

Patient Support Programmes (PSPs) are used by the pharmaceutical industry to provide education and support to consumers to overcome the challenges they face managing their condition and treatment. Whilst there is an increasing number of PSPs, limited information is available on whether these programmes contribute to safety signals. PSPs do not have a scientific hypothesis, nor are they governed by a protocol. However, by their nature, PSPs inevitably generate adverse event (AE) reports. The main goal of the research was to gather all Novartis-initiated PSPs for sacubitril/valsartan, followed by research in the company safety database to identify all AE reports emanating from these PSPs. Core data sheets (CDS) were reviewed to assess if these PSPs contributed to any new, regulatory-authority approved, validated signals. Overall, AEs entered into the safety database from PSPs confirmed no contribution to CDS updates. Detailed review of real-world data revealed tablet splitting or taking one higher dose tablet a day instead of twice daily. This research, and subsequent analyses, revealed that PSPs did not impact safety label changes for sacubitril/valsartan. It revealed an important finding concerning drug utilisation i.e. splitting of sacubitril/valsartan tablets to reduce cost. This finding suggests that PSPs may contribute important real-world data on patterns of medication usage. There remains a paucity of literature available on this topic, hence further research is required to assess if it would be worth designing PSPs for collecting data on drug utilisation and (lack of) efficacy. Such information from PSPs could be important for all stakeholders.

Material Safety Data Sheets for chemical products are available to laboratory workers for most chemicals and reagents. However because many laboratory workers, whether in research, public health, teaching, etc., are exposed to not only chemicals but infectious substances as well, there was a large gap in the readily available safety literature for employees. These MSDS are produced for personnel working in the life sciences as quick safety reference material relating to infectious micro-organisms. The MSDS are organized to contain health hazard information such as infectious dose, viability (including decontamination), medical information, laboratory hazard, recommended precautions, handling information and spill procedures. The intent of these documents is to provide a safety resource for laboratory personnel working with these infectious substances. Because these workers are usually working in a scientific setting and are potentially exposed to much higher concentrations of these human pathogens than the general public, the terminology in these MSDS is technical and detailed, containing information that is relevant specifically to the laboratory setting. It is hoped along with good laboratory practices, these MSDS will help provide a safer, healthier environment for everyone working with infectious substances. The MSDS is ran by the Public Health Agency of Canada. The Public Health Agency of Canada (PHAC) is the main Government of Canada agency responsible for public health in Canada. PHACs primary goal is to strengthen Canadas capacity to protect and improve the health of Canadians and to help reduce pressures on the health-care system. To do this, the Agency is working to build an effective public health system that enables Canadians to achieve better health and well-being in their daily lives by promoting good health, helping prevent and control chronic diseases and injury, and protecting Canadians from infectious diseases and other threats to their health. PHAC is also committed to reducing health disparities between the most advantaged and disadvantaged Canadians. Because public health is a shared responsibility, the Public Health Agency of Canada works in close collaboration with all levels of government (provincial, territorial and municipal) to build on each others skills and strengths. The Agency also works closely with non-government organizations, including civil society and business, and other countries and international organizations like the World Health Organization (WHO) to share knowledge, expertise and experiences.

Explore the comprehensive Material Safety Data Sheet (MSDS) for Methyl Tertiary Butyl Ether (MTBE), outlining its uses as a fuel additive, safety precautions, potential hazards, and recommended handling procedures to ensure safe and informed usage.

Quantitative data on product chemical composition is a necessary parameter for characterizing near-field exposure. This data set comprises reported and predicted information on >75,000 chemicals contained in >15,000 consumer products. The data’s primary intended use is for exposure, risk, and safety assessments. The data set includes specific products with quantitative or qualitative ingredient information, which has been publicly disclosed through material safety data sheets (MSDS) and ingredient lists. A single product category from a refined and harmonized set of categories has been assigned to each product. The data set also contains information on the functional role of chemicals in products, which can inform predictions of the concentrations in which they occur. These data will be useful to exposure and risk assessors evaluating chemical and product safety.

The data set presented here is in the form of a MySQL relational database, which mimics CPDat data available under the ‘Exposure’ tab of the CompTox Chemistry Dashboard (https://comptox.epa.gov/dashboard) as of August 2017.

Discover the detailed safety and handling guidelines for sodium lauryl sulfate (SLS) as outlined in the Safety Data Sheet (SDS). Learn about its potential hazards, first-aid measures, PPE recommendations, and environmental impact to ensure safe usage in personal care and industrial settings.

Abstract

The dataset was compiled by the Geological and Bioregional Assessment Program from multiple sources referenced within the dataset and/or metadata. The processes undertaken to compile this dataset are described in the History field in this metadata statement.

Attribution

Geological and Bioregional Assessment Program

History

Physico-chemical data were compiled from US EPA Estimation Programme Interface (EPI Suite). Estimated properties were based on the Simplified Molecular Input Line-Entry System (SMILES), Biowin models 1-7, PHYSPROP. Ecotoxicology data were compiled from chemical safety data sheets, eChemPortal, USEPA ECOTOX, OECD SIDS, ECHA assessments, USEPA (2015/6) reaxys database, NICNAS/IMAP assessments, ECOSAR 2.0.

This web feature service contains location and facility identification information from EPA's Facility Registry System (FRS) for the subset of facilities that link to the Emergency Response Information System (E-PLAN) provides first responders and other emergency response personnel with on-site hazardous chemical information for facilities across the us. It provides EPA’s tier II reporting data along with other important information including maps of all facilities with a specified hazardous material, chemical hazards response information system (CHRIS) data, material safety data sheets (MSDS), chemical profiles, emergency response guidebook (ERG) pages, national fire protection association (NPA) codes, and facility risk management plans (RMPs). Using vigorous verification and data management procedures, FRS integrates facility data from EPA's national program systems, other federal agencies, and State and tribal master facility records and provides EPA with a centrally managed, single source of comprehensive and authoritative information on facilities. This data set contains the subset of FRS integrated facilities that link to E-PLAN facilities once the E-PLAN data has been integrated into the FRS database. Additional information on FRS is available at the EPA website http://www.epa.gov/enviro/html/fii/index.html.

Abstract The dataset was compiled by the Geological and Bioregional Assessment Program from multiple sources referenced within the dataset and/or metadata. The processes undertaken to compile this …Show full descriptionAbstract The dataset was compiled by the Geological and Bioregional Assessment Program from multiple sources referenced within the dataset and/or metadata. The processes undertaken to compile this dataset are described in the History field in this metadata statement. Attribution Geological and Bioregional Assessment Program History Physico-chemical data were compiled from US EPA Estimation Programme Interface (EPI Suite). Estimated properties were based on the Simplified Molecular Input Line-Entry System (SMILES), Biowin models 1-7, PHYSPROP. Ecotoxicology data were compiled from chemical safety data sheets, eChemPortal, USEPA ECOTOX, OECD SIDS, ECHA assessments, USEPA (2015/6) reaxys database, NICNAS/IMAP assessments, ECOSAR 2.0.

A team of experts and scholars is formed to review genetically modified food ingredients on a case-by-case basis. This dataset allows for the inquiry of approved genetically modified food ingredients.

Data file marketing programs Novartis _30JUN2020 v1.0 (confidential data on file).

BackgroundHeart failure (HF) is a global health concern, affecting millions of individuals worldwide and leading to significant morbidity and mortality. Despite advances in conventional therapeutic strategies, the prognosis for HF patients remains challenging, and there is a constant search for novel therapeutic options. Among these, Panax quinquefolius saponin (PQS) has demonstrated promising pharmacological properties that may benefit HF. However, the efficacy and safety of PQS for HF have not been comprehensively evaluated.ObjectiveThis systematic review and meta-analysis aim to provide a more reliable estimation of the efficacy and safety of PQS for HF. This will help clinicians make informed decisions regarding the potential use of PQS in managing HF patients.MethodsWe comprehensively and systematically searched for published randomized controlled trials (RCTs) in the following eight electronic databases: PubMed, Cochrane Library, EMBASE, Web of Science (WOS), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Wanfang Data, and China Biology Medicine Database (CBM) from database inception to March 2024. The Cochrane risk of bias (ROB 2.0) assessment tool was used for quality assessment, and Review Manager (RevMan, version 5.4) was used for meta-analysis. Mean difference (MD), 95% credible interval (CI), and relative risk (RR) estimates were calculated under a random-effects model. We also used GRADE profiler (GRADEpro, version 3.6) to analyze the quality of outcomes. In addition, the protocol has been registered in International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) under registry number 202440050.ResultsThis study included nine RCTs involving a total of 952 patients with HF. The results of a meta-analysis under a random-effects model showed that adjuvant PQS therapy significantly increased LVEF (MD = 6.23, 95% CI [4.35, 8.12], P < 0.00001), 6MWTD (MD = 25.26, 95% CI [8.23, 42.30], P = 0.004), and decreased BNP/NT-pro-BNP (MD = −187.94, 95% CI [−267.20, −108.67], P < 0.00001), LVEDV (MD = −22.83, 95% CI [−42.79, −2.87], P = 0.02), LVEDD (MD = −4.76, 95% CI [−5.77, −3.74], P < 0.00001), and LVESV (MD = −11.86, 95% CI [−19.89, −3.83], P = 0.004) in patients with HF.ConclusionThe evidence provided by this systematic review suggests that adjunctive PQS therapy for HF can improved clinical efficacy and holds potential advantages in improving cardiac function and increasing exercise tolerance. However, given the limitations inherent in this review, the conclusions of this study should be interpreted cautiously. Therefore, in clinical practice, it is recommended that physicians tailor treatment strategies according to the specific circumstances of individual patients.Systematic Review registrationhttps://inplasy.com/?s=202440050

IntroductionTo date, only two drugs, pirfenidone and nintedanib, are approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). In addition, very few studies have reported on the safety profile of either drug in large populations. This study aims to identify and compare adverse drug events (ADEs) associated with pirfenidone and nintedanib in real-world settings by analyzing data from the US Food and Drug Administration Adverse Event Reporting System (FAERS). In addition, we utilized data from the Japanese Adverse Drug Event Report (JADER) database for external validation.MethodsThe ADE reports on both drugs from 2014 Q3 to 2024 Q2 in FAERS and from 2008 Q1 to 2024 Q1 in JADER were collected. After deduplication, Bayesian and non-Bayesian methods for disproportionality analysis, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multiple Gamma Poisson Shrinkers (MGPS), were used for signal detection. Additionally, time to onset (TTO) analysis were performed.ResultsIn total, 35,804 and 20,486 ADE reports were identified from the FAERS database for pirfenidone and nintedanib, respectively. At the system organ class (SOC) level, both drugs have a positive signal value for “gastrointestinal disorders,” “respiratory, thoracic, and mediastinal disorders,” and “metabolism and nutrition disorders.” Other positive signals for pirfenidone include “general disorders and administration site conditions,” and “skin and subcutaneous tissue disorders,” while for nintedanib, they were “investigations,” “infections and infestations,” and “hepatobiliary disorders.” Some positive signals were consistent with the drug labels, including nausea, decreased appetite, and weight decreased identified in pirfenidone, as well as diarrhea, decreased appetite, abdominal pain upper, and epistaxis identified in nintedanib. We also identified unexpected signals not listed on the drug label, such as decreased gastric pH, and pneumothorax for pirfenidone, and constipation, flatulence for nintedanib. The median onset time for ADEs was 146 days for pirfenidone and 45 days for nintedanib, respectively. Although the two antifibrotics differed in the proportion of periods in which the ADEs occurred, these ADEs were likely to continue even after a year of treatment. In the external validation of JADER, the number of reports for pirfenidone and nintedanib were 265, and 1,327, respectively. The disproportionality analysis at the SOC and preferred term (PT) levels supports the FAERS results.ConclusionThis study systematically investigates and compares the ADEs and their onset times at the SOC and specific PT levels for pirfenidone and nintedanib. Our results provide valuable pharmacological insights for the similarities and differences between the safety profiles of the two drugs and highlight the importance of monitoring and managing the toxicity profile associated with antifibrotic drugs.

IntroductionThe healthcare sector is globally experiencing increasing demands and workplace interventions on an organisational level is sought to create healthy workplaces. The aim of this study was to provide an overview of Nordic research on the work environment and health of healthcare professionals, with a focus on identifying organisational-level risk and health-promoting factors.MethodsThis systematic search and review was based on an analysis of studies published in peer-reviewed journals between 1 January 2016 and 3 January 2023. The selected studies investigate the relationships between organisational-level risk and health-promoting factors and measures of health and well-being among healthcare professionals during ordinary operations. To increase applicability, this systematic search and review was limited to the Nordic countries as they share the same context with a publicly-funded widely accessible healthcare system. A total of 2,677 articles were initially identified, with 95 original studies meeting the criteria for relevance and quality.ResultsIdentified organisational risk and health-promoting factors were categorised into five categories: work schedule distribution, operations design and work methods, ergonomic conditions, working conditions and personnel policies, and the organisation’s ethical environment. In addition, two themes across the categories emerged, providing further insight into the implications for practice. The first theme emphasises risk and health-promoting factors in the actions that employers take to fulfil the organisation’s goals. The second theme emphasises risk and health-promoting factors in connection with the ability of employees to do their jobs at a level of quality they deem acceptable.ConclusionSeveral organisational-level risk and health-promoting factors were identified, and the results indicate that the actions that employers take to fulfil the health-care organisation’s goals and promote the ability of employees to provide high-quality care are important for the health and wellbeing of healthcare employees.

IntroductionThe healthcare sector is globally experiencing increasing demands and workplace interventions on an organisational level is sought to create healthy workplaces. The aim of this study was to provide an overview of Nordic research on the work environment and health of healthcare professionals, with a focus on identifying organisational-level risk and health-promoting factors.MethodsThis systematic search and review was based on an analysis of studies published in peer-reviewed journals between 1 January 2016 and 3 January 2023. The selected studies investigate the relationships between organisational-level risk and health-promoting factors and measures of health and well-being among healthcare professionals during ordinary operations. To increase applicability, this systematic search and review was limited to the Nordic countries as they share the same context with a publicly-funded widely accessible healthcare system. A total of 2,677 articles were initially identified, with 95 original studies meeting the criteria for relevance and quality.ResultsIdentified organisational risk and health-promoting factors were categorised into five categories: work schedule distribution, operations design and work methods, ergonomic conditions, working conditions and personnel policies, and the organisation’s ethical environment. In addition, two themes across the categories emerged, providing further insight into the implications for practice. The first theme emphasises risk and health-promoting factors in the actions that employers take to fulfil the organisation’s goals. The second theme emphasises risk and health-promoting factors in connection with the ability of employees to do their jobs at a level of quality they deem acceptable.ConclusionSeveral organisational-level risk and health-promoting factors were identified, and the results indicate that the actions that employers take to fulfil the health-care organisation’s goals and promote the ability of employees to provide high-quality care are important for the health and wellbeing of healthcare employees.